Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death globally. Viral hepatitis, specifically hepatitis B and hepatitis C infections are a major cause of HCC. Antiviral therapies for both HBV and HCV infection can decrease the risk of HCC. This presentation will focus on the contribution of HCC to global liver-related mortality and the impact of antiviral therapies on the incidence of HCC. This presentation will discuss the emerging data on the impact of direct-acting antivirals (DAA) on HCC incidence and recurrence and on the role of DAA therapies in patients diagnosed with HCC. In particular, the presentation will discuss in detail (1) the evidence supporting the safety of DAA therapies in patients with cirrhosis as it relates to risk of HCC development, (2) the optimal timing for initiating DAA therapy in patients who have been diagnosed with HCC and will discuss the impact, if any, of HCC diagnosis on response to DAA therapy, and (3) the impact of SVR on HCC incidence. Lastly, the presentation will discuss monitoring for HCC after SVR in patients with HCC and will highlight emerging non-invasive biomarkers that may be utilized after DAA HCV cure to improve risk stratification. When possible the presentation will discuss differences in HCC presentation and outcome in people with HIV and viral hepatitis.